Contribution: Industrial Research Assistance Program – Contributions to Firms
Azor Biotek Inc.
$30,000.00
Evaluation of molecules proposed to modulate miR processivity
FY 2021-22 · 2021-04-01
Summary
This project aims to provide in vitro biophysical data as proof-of-concept for a drug discovery platform that targets misexpressed miRNA. This pilot study investigates therapeutic targets of Parkinson's disease and pulmonary fibrosis, a sequela of COVID-19 infection.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Victoria|Victoria, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
703340513
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-04-01 | 2021-22 | $30,000.00 |
| 1 | 2021-04-01 | 2021-22 | $30,000.00 |
| 2 | 2021-04-01 | 2021-22 | $30,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 75 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 75 jours.
Agreement End Date
2022-03-31
Agreement Number
969160
Agreement Start Date
2021-04-01
Agreement Title
Evaluation of molecules proposed to modulate miR processivity
Agreement Title (French)
Évaluation des molécules proposées pour moduler la processivité des miR
Agreement Type
Contribution
Agreement Value
$30,000.00
Amendment Date
2022-01-13
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project aims to provide in vitro biophysical data as proof-of-concept for a drug discovery platform that targets misexpressed miRNA. This pilot study investigates therapeutic targets of Parkinson's disease and pulmonary fibrosis, a sequela of COVID-19 infection.
Description (French)
Ce projet vise à fournir des données biophysiques in vitro comme preuve de concept pour une plateforme de découverte de médicaments qui cible les miRNA mal exprimés. Cette étude pilote porte sur des cibles thérapeutiques de la maladie de Parkinson et de la fibrose pulmonaire, une séquelle de l'infection par la COVID-19.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Victoria
Federal Riding (French)
Victoria
Federal Riding Number
59041
NAICS Code
325410
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
703340513
Recipient City
Victoria|Victoria
Recipient Country
CA
Recipient Legal Name
Azor Biotek Inc.
Recipient Postal Code
V8S 4T8
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2020-2021-Q4-969160
